• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMylan

Why a Democratic Senator Is Supporting Mylan’s CEO

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
September 7, 2016, 5:55 PM ET
President Obama Delivers State Of The Union Address
WASHINGTON, DC - JANUARY 20: House Minority Leader Nancy Pelosi (R) (D-CA) talks with Sen. Joe Manchin (L) (D-WV) before the start of the State of the Union speech in the House chamber of the U.S. Capitol January 20, 2015 in Washington, DC. U.S. President Barack Obama was expected to lay out a broad agenda including attempts to address income inequality and making it easier for Americans to afford college education and child care. (Photo by Rob Carr/Getty Images)Photograph by Rob Carr—via Getty Images

Mylan (MYL) CEO Heather Bresch isn’t the most popular among the public and lawmakers right now. But at least one elected official is singing her praises: her father, Senator Joe Manchin (D-W.Va.).

Bresch and her pharma company have been staring down a deluge of criticism for hiking the price of the EpiPen, a device used to fight potentially lethal allergic reactions, by more than 400% over the last decade. Members of Congress have called for a formal investigation, while New York attorney general Eric Schneiderman announced Tuesday that he’d launched an antitrust probe into Mylan for potentially putting anti-competitive language into its contracts with local school districts.

Manchin, however, defended his daughter in an interview with Bloomberg on Tuesday evening.

Click here to subscribe to our new Brainstorm Health Daily Newsletter.

“My daughter is my daughter with unconditional love and she’s the most amazing person that I know of as far as not only being accomplished, but just, she’s so compassionate and generous in how she’s always lived her life,” he said.

Manchin went on to say that his daughter would make sure anyone who informed Mylan they couldn’t afford an EpiPen would undoubtedly receive one. “[S]he would give them one,” he said. “That’s all. I know that. I know her well enough to know that would happen.”

Mylan has significantly boosted its coupons for patients since the firestorm over the EpiPen and plans to introduce a generic competitor to its own product at half the price.

 

Manchin acknowledge that he knew little about Mylan’s individual business practices and called drug pricing a “convoluted” issue. But he assured that his daughter would answer any of his colleagues’ questions about pricing and hoped that Bresch would receive a fair shake.

By shining light on high drug prices and price hikes, which are common throughout the biopharma industry, Manchin said all the attention the EpiPen’s tab could be a “blessing in disguise.”

“They are all too expensive,” he said. “So if there is a way to find out that we can deliver it at a better, more economical price, and still have the innovative and creative juices flowing I guess that makes all these things happen, you’ve got to find the balance somewhere.”

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

hoskins
Commentaryoffices
Gensler Co-Chair: Hot-desking was supposed to save money. It may be costing you your culture
By Diane HoskinsApril 30, 2026
6 hours ago
raw milk
Politicsmilk
Risk of paralysis, bacteria, even death is no match for Americans’ thirst for raw milk
By Laura Ungar, Jonel Aleccia and The Associated PressApril 29, 2026
21 hours ago
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
HealthDietary Supplements
The Best Protein Shakes of 2026: Tasted and Approved by Nutrition Experts
By Christina SnyderApril 29, 2026
1 day ago
aging
HealthLongevity
We’re the CEOs of Peloton and the Hospital for Special Surgery. Living longer isn’t enough, we need to live better, too
By Bryan T. Kelly and Peter SternApril 29, 2026
1 day ago
Bruce Broussard, HP CEO
AIProductivity
AI is changing who gets to be an expert. Are your colleagues ready to become ‘directors of intelligence’?
By Bruce BroussardApril 29, 2026
1 day ago
Robert F. Kennedy Jr. sits at a cafeteria table with schoolchildren.
EconomyEducation
More than two-thirds of U.S. schools say they’re unable to afford the cost of student free lunch—and MAHA’s dietary guidelines may make it worse
By Sasha RogelbergApril 29, 2026
1 day ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
22 hours ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
1 day ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
2 days ago
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
Big Tech
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
By Alexei OreskovicApril 29, 2026
15 hours ago
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
Energy
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
By Shawn TullyApril 29, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.